Trial Profile

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 25 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Carcinoid tumour; Gastrointestinal cancer; Lung cancer; Malignant thymoma; Neuroendocrine carcinoma; Pancreatic cancer
Focus Registrational; Therapeutic Use
Acronyms CABINET

Most Recent Events

20 Jun 2025 According to an Ipsen media release, a final decision on the approval of this drug in the European Union is expected in Q3 2025.
20 Jun 2025 Results presented in the Ipsen media release.
20 Jun 2025 According to an Ipsen media release, data from this trial was presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com